Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMF-500 in Adults With Acute Leukemia
NCT05918692Phase 1Completed
- Sponsor
- Biomea Fusion
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMF-500 in acute myeloid leukemia (AML) (3 arms), sponsored by Biomea Fusion. Primary endpoints: Treatment Emergent Adverse Events, Serious Adverse Events and 1 more. Started Jul 2023; status: completed.
02
Drugs
BMF-500
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05918692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918692.